Bibliografia del Gruppo Mito

Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). Target Oncol. 2018 Aug;13(4):469-479. doi:
10.1007/s11523-018-0574-1. PubMed PMID: 29948780.

Farolfi A, Petrone M, Scarpi E, Gallà V, Greco F, Casanova C, Longo L, Cormio G, Orditura M, Bologna A, Zavallone L, Ventriglia J, Franzese E, Loizzi V, Giardina D, Pigozzi E, Cioffi R, Pignata S, Giorda G, De Giorgi U.

Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer. J Clin Oncol. 2018 May 1;36(13):1300-1307. doi:
10.1200/JCO.2017.76.2781. Epub 2018 Mar 20. PubMed PMID: 29558274.

Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, Van Le L, Ghamande S, González-Santiago S, Bover I, Graña Suárez B, Green A, Huot-Marchand P, Bourhis Y, Karve S, Blakeley C.

Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. Eur J Surg Oncol. 2019 Jan;45(1):67-74. doi:
10.1016/j.ejso.2017.09.025. Epub 2017 Nov 3. Review. PubMed PMID: 29108961.
Ray-Coquard I, Trama A, Seckl MJ, Fotopoulou C, Pautier P, Pignata S,Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E,Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA; RARECARENet Working
Group

SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3
trial. Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25. Erratum in: Lancet Oncol. 2017 Sep;18(9):e510. PubMed PMID: 28754483.

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P;

GCIG Symptom
Benefit group. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. Oncologist. 2017 Sep;22(9):1117-1124. doi:
10.1634/theoncologist.2017-0047. Epub 2017 Jun 8. PubMed PMID: 28596446; PubMed Central PMCID: PMC5599194.

Roncolato FT, Joly F, O'Connell R, Lanceley A, Hilpert F, Buizen L, Okamoto A,Aotani E, Pignata S, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Heitz F,Feeney A, Berton-Rigaud D, Stockler MR, King M, Friedlander M;

A miRNA signature assessing ovarian cancer prognosis. Oncoscience. 2016 Dec 2;3(11-12):308-310. doi:
10.18632/oncoscience.329. eCollection 2016. PubMed PMID: 28105451; PubMed Central
PMCID: PMC5235915.

Bagnoli M, Pignata S, Mezzanzanica D.

Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. Gynecol Oncol. 2017 Jan;144(1):72-76. doi:
10.1016/j.ygyno.2016.10.023. Epub 2016 Oct 27. PubMed PMID: 28094039.

Bergamini A, Pisano C, Di Napoli M, Arenare L, Della Pepa C, Tambaro R,
Facchini G, Gargiulo P, Rossetti S, Mangili G, Pignata S, Cecere SC.

Second-line dovitinib
(TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncol. 2015 Jun;16(6):686-94. doi:
10.1016/S1470-2045(15)70159-2. Epub 2015 May 13. PubMed PMID: 25981814.

Konecny GE, Finkler N, Garcia AA, Lorusso D, Lee PS, Rocconi RP, Fong PC, Squires M, Mishra K, Upalawanna A, Wang Y, Kristeleit R.

Gynecologic Cancer InterGroup (GCIG)
consensus review for clear cell carcinoma of the uterine corpus and cervix. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S90-5. doi: 10.1097/IGC.0000000000000297.
Review. PubMed PMID: 25341588.

Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glasspool RM, Devouassoux-Shisheboran M, Covens A, Lorusso D, Kurzeder C, Kim JW, Gladieff L, Bryce J, Friedlander M, Fujiwara K.

Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A
Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or
primary peritoneal cancer. Int J Gynecol Cancer. 2019 Jan 10. pii: ijgc-2018-000071. doi: 10.1136/ijgc-2018-000071. [Epub ahead of print] PubMed PMID: 30630885.

Moore KN, Pignata S.

Randomized Phase II Trial of Ridaforolimus in
Advanced Endometrial Carcinoma. J Clin Oncol. 2015 Nov 1;33(31):3576-82. doi:
10.1200/JCO.2014.58.8871. Epub 2015 Jun 15. PubMed PMID: 26077241.

Oza AM, Pignata S, Poveda A, McCormack M, Clamp A, Schwartz B, Cheng J, Li X, Campbell K, Dodion P, Haluska FG.

A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian
Cancer and Gynecologic Malignancies) group. Br J Cancer. 2007 Jun 4;96(11):1639-43. Epub 2007 May 8. PubMed PMID: 17486128; PubMed Central PMCID: PMC2359926.

Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, Ferrandina G, Lorusso D, Zagonel V, Febbraro A, Riva N, De Rosa V, Gallo C, Perrone F; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group.

ESMO Guidelines Committee. Non-epithelial ovarian cancer: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Supplement_4):iv1-iv18. doi: 10.1093/annonc/mdy001. PubMed PMID: 29697741.

Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, Colombo N;

Laparoscopic surgery in the treatment of stage I adult
granulosa cells tumors of the ovary: Results from the MITO-9 study. Eur J Surg
Oncol. 2018 Jun;44(6):766-770. doi: 10.1016/j.ejso.2018.03.001. Epub 2018 Mar 10.
PubMed PMID: 29576462.

Bergamini A, Ferrandina G, Candiani M, Cormio G, Giorda G, Lauria R, Perrone AM, Scarfone G, Breda E, Savarese A, Frigerio L, Gadducci A, Mascilini F, Maneschi F, Cassani C, Marchetti C, Cecere SC, Biglia N, De Giorgi U, Raspagliesi
F, Lorusso D, Mangili G.

Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1,
GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. Ann Oncol. 2018 May 1;29(5):1189-1194. doi: 10.1093/annonc/mdy062. PubMed PMID: 29462248.

Piccirillo MC, Scambia G, Bologna A, Signoriello S, Vergote I, Baumann K, Lorusso D, Murgia V, Sorio R, Ferrandina G, Sacco C, Cormio G, Breda E, Cinieri S, Natale D, Mangili G, Pisano C, Cecere SC, Di Napoli M, Salutari V, Raspagliesi
F, Arenare L, Bergamini A, Bryce J, Daniele G, Gallo C, Pignata S, Perrone F.

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study
(SBS). Gynecol Oncol. 2018 Jan;148(1):36-41. doi: 10.1016/j.ygyno.2017.10.019.
Epub 2017 Oct 26. PubMed PMID: 29107348.

Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M.

Role of adjuvant chemotherapy in early-stage
endometrioid and clear-cell ovarian cancer. Ann Oncol. 2017 Dec
1;28(12):2909-2911. doi: 10.1093/annonc/mdx539. PubMed PMID: 28950371.

Lorusso D, Pignata S.

ARIEL3 investigators.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Oct 28;390(10106):1949-1961. doi:
10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12. Erratum in: Lancet. 2017 Oct 28;390(10106):1948. PubMed PMID: 28916367; PubMed Central PMCID: PMC5901715.

Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA;

Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval
Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. J Clin Oncol. 2017 Oct 10;35(29):3347-3353.
doi: 10.1200/JCO.2017.73.4293. Epub 2017 Aug 21. PubMed PMID: 28825853.

Pignata S, Scambia G, Bologna A, Signoriello S, Vergote IB, Wagner U, Lorusso D, Murgia V, Sorio R, Ferrandina G, Sacco C, Cormio G, Breda E, Cinieri S, Natale D, Mangili G, Pisano C, Cecere SC, Di Napoli M, Salutari V, Raspagliesi F, Arenare L, Bergamini A, Bryce J, Daniele G, Piccirillo MC, Gallo C, Perrone F.

Emesis and nausea related to single agent
trabectedin in ovarian cancer patients: a sub-study of the MITO15 project.
Support Care Cancer. 2017 Jun;25(6):1743-1748. doi: 10.1007/s00520-016-3547-x.
Epub 2017 Jan 19. PubMed PMID: 28101677.

Di Napoli M, Della Pepa C, Arenare L, Scambia G, Lorusso D, Raspagliesi F, Ferrandina G, Salutari V, Sorio R, Mosconi AM, Mangili G, Borgato L, Lepori S, Salvino A, Pignata S, Cecere SC.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer
InterGroup: recurrent disease. Ann Oncol. 2017 Apr 1;28(4):727-732. doi:
10.1093/annonc/mdw663. PubMed PMID: 27993805; PubMed Central PMCID: PMC6246494.

Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, du Bois A, Vergote I, Reuss A, Bacon M, Friedlander M, Gallardo-Rincon D, Joly F, Chang SJ, Ferrero AM, Edmondson RJ, Wimberger P, Maenpaa J, Gaffney D, Zang R, Okamoto A, Stuart G, Ochiai K; participants of the Fifth Ovarian Cancer Consensus Conference.

Feasibility and outcome of interval
debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A
subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. Gynecol Oncol. 2017
Feb;144(2):256-259. doi: 10.1016/j.ygyno.2016.12.011. Epub 2016 Dec 16. PubMed
PMID: 27993479.

Daniele G, Lorusso D, Scambia G, Cecere SC, Nicoletto MO, Breda E, Colombo N, Artioli G, Cannella L, Lo Re G, Raspagliesi F, Maltese G, Salutari V, Ferrandina G, Greggi S, Baldoni A, Bergamini A, Piccirillo MC, Tognon G, Floriani I, Signoriello S, Perrone F, Pignata S.

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of
pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer.
2017 Jan;70:111-121. doi: 10.1016/j.ejca.2016.09.004. Epub 2016 Dec 1. PubMed
PMID: 27914241.

Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl
FD, Bach BA.

The role of staging and adjuvant chemotherapy in stage I malignant ovarian
germ cell tumors (MOGTs): the MITO-9 study. Ann Oncol. 2017 Feb 1;28(2):333-338.
doi: 10.1093/annonc/mdw563. PubMed PMID: 27803008.

Mangili G, Sigismondi C, Lorusso D, Cormio G, Candiani M, Scarfone G, Mascilini F, Gadducci A, Mosconi AM, Scollo P, Cassani C, Pignata S, Ferrandina G.

Brain metastases in patients with EOC:
Clinico-pathological and prognostic factors. A multicentric retrospective
analysis from the MITO group (MITO 19). Gynecol Oncol. 2016 Dec;143(3):532-538.
doi: 10.1016/j.ygyno.2016.09.025. Epub 2016 Oct 5. PubMed PMID: 27717490.

Marchetti C, Ferrandina G, Cormio G, Gambino A, Cecere S, Lorusso D, De Giorgi U, Bogliolo S, Fagotti A, Mammoliti S, Narducci F, Bergamini A, Scollo P, Biglia N, Breda E, Tamberi S, Marinaccio M, Angioli R, Salerno L, Eusebi MC,
Loizzi V, Scambia G, Panici PB.

ENGOT-OV16/NOVA Investigators. Niraparib Maintenance Therapy in
Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec
1;375(22):2154-2164. Epub 2016 Oct 7. PubMed PMID: 27717299.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P,
Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA;

Biomarker analysis of the MITO2 phase
III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK
and phosphorylated ACC. Oncotarget. 2016 Nov 8;7(45):72654-72661. doi:
10.18632/oncotarget.12056. PubMed PMID: 27655643; PubMed Central PMCID:
PMC5341934.

Perrone F, Baldassarre G, Indraccolo S, Signoriello S, Chiappetta G, Esposito F, Ferrandina G, Franco R, Mezzanzanica D, Sonego M, Zulato E, Zannoni GF, Canzonieri V, Scambia G, Sorio R, Savarese A, Breda E, Scollo P, Ferro A, Tamberi
S, Febbraro A, Natale D, Di Maio M, Califano D, Scognamiglio G, Lorusso D, Canevari S, Losito S, Gallo C, Pignata S.

Development and validation of a microRNA-based signature (MiROvaR) to
predict early relapse or progression of epithelial ovarian cancer: a cohort
study. Lancet Oncol. 2016 Aug;17(8):1137-1146. doi:
10.1016/S1470-2045(16)30108-5. Epub 2016 Jul 9. PubMed PMID: 27402147.

Bagnoli M, Canevari S, Califano D, Losito S, Maio MD, Raspagliesi F, Carcangiu ML, Toffoli G, Cecchin E, Sorio R, Canzonieri V, Russo D, Scognamiglio G, Chiappetta G, Baldassarre G, Lorusso D, Scambia G, Zannoni GF, Savarese A,
Carosi M, Scollo P, Breda E, Murgia V, Perrone F, Pignata S, De Cecco L, Mezzanzanica D; Multicentre Italian Trials in Ovarian cancer (MITO) translational
group.

Double-Blind,
Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined
With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3
mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). J Clin Oncol. 2016
Jul 20;34(21):2516-25. doi: 10.1200/JCO.2015.66.0787. Epub 2016 Jun 6. PubMed
PMID: 27269942.

Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A,
Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A.

Prospective phase II trial
of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer
patients: the MITO 15 trial. Ann Oncol. 2016 Mar;27(3):487-93. doi:
10.1093/annonc/mdv608. Epub 2015 Dec 17. PubMed PMID: 26681678.

Lorusso D, Scambia G, Pignata S, Sorio R, Amadio G, Lepori S, Mosconi A, Pisano C, Mangili G, Maltese G, Sabbatini R, Artioli G, Gamucci T, Di Napoli M, Capoluongo E, Ludovini V, Raspagliesi F, Ferrandina G.

Pazopanib plus weekly
paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015 May;16(5):561-8. doi:
10.1016/S1470-2045(15)70115-4. Epub 2015 Apr 14. PubMed PMID: 25882986.

Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA, Arcangeli V, Panici PB, Pisano C, Cecere SC, Di Napoli M, Raspagliesi F, Maltese G, Salutari V, Ricci C, Daniele G, Piccirillo
MC, Di Maio M, Gallo C, Perrone F; MITO 11 investigators.

Is the endometrial evaluation
routinely required in patients with adult granulosa cell tumors of the ovary?
Gynecol Oncol. 2015 Feb;136(2):230-4. doi: 10.1016/j.ygyno.2014.12.016. Epub 2014
Dec 17. PubMed PMID: 25527364.

Ottolina J, Ferrandina G, Gadducci A, Scollo P, Lorusso D, Giorda G, Breda E, Savarese A, Candiani M, Zullo F, Mangili G.

Gynecologic Cancer InterGroup (GCIG)
consensus review for clear cell carcinoma of the uterine corpus and cervix. Int J
Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S90-5. doi: 10.1097/IGC.0000000000000297.
Review. PubMed PMID: 25341588.

Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glasspool RM, Devouassoux-Shisheboran M, Covens A, Lorusso D, Kurzeder C, Kim JW, Gladieff L, Bryce J, Friedlander M, Fujiwara K.

Gynecologic Cancer
Intergroup (GCIG) consensus review for ovarian germ cell tumors. Int J Gynecol
Cancer. 2014 Nov;24(9 Suppl 3):S48-54. doi: 10.1097/IGC.0000000000000223. Review.
PubMed PMID: 25341580.

Brown J, Friedlander M, Backes FJ, Harter P, O'Connor DM, de la Motte Rouge T, Lorusso D, Maenpaa J, Kim JW, Tenney ME, Seckl MJ.

Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the
ovary. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S35-41. doi:
10.1097/IGC.0000000000000265. Review. PubMed PMID: 25341578.

Reed NS, Gomez-Garcia E, Gallardo-Rincon D, Barrette B, Baumann K, Friedlander M, Kichenadasse G, Kim JW, Lorusso D, Mirza MR, Ray-Coquard I.

Trophoblastic disease review for diagnosis and management: a joint report
from the International Society for the Study of Trophoblastic Disease, European
Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic
Cancer InterGroup. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S109-16. doi:
10.1097/IGC.0000000000000294. Review. PubMed PMID: 25341573.

Mangili G, Lorusso D, Brown J, Pfisterer J, Massuger L, Vaughan M, Ngan HY, Golfier F, Sekharan PK, Charry RC, Poveda A, Kim JW, Xiang Y, Berkowtiz R, Seckl MJ.